Loading...
•
Mar 31, 2020
Veracyte Q1 2020 Earnings Report
Reported solid results for the first quarter of 2020, with strong revenue and volume growth across the genomic testing business.
Key Takeaways
Veracyte announced financial results for Q1 2020, featuring a 20% increase in total testing and product revenue to $30.4 million and a 15% growth in genomic testing volume. The company also secured strategic collaborations and advanced its pipeline.
Total testing and product revenue increased by 20% to $30.4 million.
Total revenue, including biopharmaceutical revenue, increased by 5% to $31.1 million.
Genomic test volume grew by 15% to 10,559 tests.
Net loss was $(11.7) million, or $(0.24) per share.
Revenue by Segment
Forward Guidance
Veracyte anticipates impact to their business from the pandemic through 2020, but believe they are well-positioned to emerge strong over the long term due to the fundamental strength and diversification of their business, as well as their strong cash position.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...